
Cell therapy pioneer Mark Frohlich takes the helm at tiny Indapta as a suite of big-name backers jump aboard
Off-the-shelf cell therapy has become a red-hot field of investment in recent years as the first rounds of human data start rolling out. Now, cell therapy startup Indapta Therapeutics is bringing in the big guns to drive its pipeline forward — including one of the field’s most esteemed names.
San Francisco-based Indapta has appointed Mark Frohlich, who previously ran portfolio strategy at Juno and before that the clinic shop at Dendreon, as its newest CEO, replacing founding helmsman Guy DiPierro, who will step into the role of chief strategy officer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.